Elsevier

Gait & Posture

Volume 11, Issue 1, February 2000, Pages 67-79
Gait & Posture

Review
Recommendations for the use of botulinum toxin type A in the management of cerebral palsy

https://doi.org/10.1016/S0966-6362(99)00054-5Get rights and content

Abstract

Botulinum toxin type A (BTX-A) is increasingly being used for the treatment of childhood spasticity, particularly cerebral palsy. However, until very recently, all such use in this indication has been unapproved with no generally accepted treatment protocols, resulting in considerable uncertainty and variation in its use as a therapeutic agent. In view of the increasing awareness of, and interest in, this approach to the treatment of spasticity, and also the recent licensing in a number of countries of a BTX-A preparation for treating equinus deformity in children, it would seem timely to establish a framework of guidelines for the safe and efficacious use of BTX-A for treating spasticity in children. This paper represents an attempt, by a group of 15 experienced clinicians and scientists from a variety of disciplines, to arrive at a consensus and produce detailed recommendations as to appropriate patient selection and assessment, dosage, injection technique and outcome measurement. The importance of adjunctive physiotherapy, orthoses and casting is also stressed.

Introduction

The use of botulinum toxin type A (BTX-A) for treating spasticity and in particular, the motor problems of children with cerebral palsy, has attracted much attention, both in clinical publications and the popular press. Until very recently, all such use has been unapproved for this indication, since BTX-A (BOTOX®, Allergan and Dysport®, Ipsen) has only been approved for the treatment of blepharospasm, hemifascial spasm, and in some countries, strabismus and cervical dystonia. This, combined with the unusual pharmacokinetic properties and potential toxicity of BTX-A, not to mention the considerable clinical challenge presented by a disorder as complex as cerebral palsy, has resulted in uncertainty about appropriate administration and dosage. Whether widespread use of BTX-A for treating spasticity is justified by the available clinical evidence [1] has been questioned. The recent licensing of BOTOX® for the treatment of equinus deformity in children in several European countries and Australia, together with pending applications for approval elsewhere, further increases the need for a discussion about the value, limitations and appropriate use of BTX-A. This paper follows detailed discussions by all of the authors at a roundtable meeting and represents an attempt, by a group of experienced users of BTX-A, to review developments and produce a clear, detailed and logical set of guidelines for the responsible use of BTX-A in the treatment of children with cerebral palsy. Many of the authors have between 4 and 6 years’ experience of treating spasticity in children by injecting BTX-A, and their combined experience represents more than 1000 children treated for this indication. In many cases this is in addition to an even greater prior experience of using BTX-A for treating dystonia in adults.

Section snippets

Biochemistry

BTX-A is a protein exotoxin derived from Clostridium botulinum. It binds, with high affinity and specificity, to the presynaptic membranes of cholinergic motor neurones, and is then internalised [2]. Once inside the cell, one of its two subunits specifically cleaves components of the cell’s exocytotic machinery (a protein known as synaptosome-associated protein of 25 kDa) so that the discharge of acetylcholine-containing vesicles, and hence neurotransmission at the neuromuscular junction, is

Patient selection and timing of treatment

BTX-A provides a useful way of controlling excessive muscular contraction in the specific muscles injected. It follows that it is most effective in patients with dynamic muscle shortening which is localised to a few muscles. The more this picture is complicated by long-standing contractures and deformity, then the less applicable it is likely to be. Results are also likely to be best in patients who have adequate selective motor control. At what point the spasticity is regarded as ‘generalised’

Physiotherapy

An active physiotherapy programme remains central to treatment, with targeted motor training aiming to achieve carry-over improvements which persist beyond the effects of the injections. Paediatric physiotherapists have an important role in selecting and teaching specific motor tasks for children to practice under the guidance of their caregivers. The physiotherapist encourages practice in an appropriate environment to achieve retention and carry-over of motor skills, as well as maintenance of

Lower limb

What follows are brief guidelines only. A full understanding of the biomechanics of movement at the hip, knee and ankle during gait is crucial to the correct and appropriate use of BTX-A injection.

  • Consider the whole child; evaluate all three levels of the lower limb (i.e. trunk/pelvis in relation to the hip, knee, ankle/foot).

  • Focus on one or two levels and select the most appropriate target muscles for injection. In more severe cases consider the medial hamstrings and adductors, in less severe

Conclusions

The contributors to this paper represent a wide range of clinical experience and backgrounds, and yet it was remarkable how quickly a consensus on the core issues discussed (patient selection, dosage, injection procedures) was reached. As a result, we feel that we can put forward these recommendations with some confidence. Clearly, on matters of more complexity, such as the use and timing of adjunctive treatments, and the treatment of difficult cases with more generalised spasticity, there is

References (52)

  • J. Blasi et al.

    Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25

    Nature

    (1993)
  • G. Borodic et al.

    Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections

    Mov. Disord.

    (1994)
  • A. De Paiva et al.

    Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals

    Proc. Natl. Acad. Sci. USA

    (1999)
  • G. Borodic

    Botulinum toxin potency: a mystery resolved by the median paralysis unit

    J. R. Soc. Med.

    (1994)
  • K. Wohlfarth et al.

    Botulinum A toxins: units versus units

    Naunyn-Schmiedeberg’s Arch. Pharmacol.

    (1997)
  • C. Sampaio et al.

    DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A — Dysport and BOTOX — assuming a ratio of 4:1

    Mov. Disord.

    (1997)
  • A.P. Cosgrove et al.

    Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse

    Dev. Med. Child Neurol.

    (1994)
  • L.A. Koman et al.

    Management of spasticity cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial

    J. Pediatr. Orthop.

    (1994)
  • I. Corry et al.

    Botulinum toxin A in the hemiplegic upper limb: a double-blind trial

    Dev. Med. Child Neurol.

    (1997)
  • A.P. Cosgrove et al.

    Botulinum toxin in the management of the lower limb in cerebral palsy

    Dev. Med. Child Neurol.

    (1994)
  • I. Corry et al.

    Botulinum toxin A compared with stretching casts in the treatment of spastic equinus, a randomised prospective trial

    J. Pediatr. Orthop.

    (1998)
  • H. Wiegand et al.

    125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection

    Naunyn-Schmiedeberg’s Arch. Pharmacol.

    (1976)
  • H. Wellhöner et al.

    Local tetanus in cats: neuropharmacokinetics of 125I-tetanus toxin

    Naunyn-Schmiedeberg’s Arch. Pharmacol.

    (1973)
  • H. Wellhöner et al.

    Local tetanus in cats: the influence of neuromuscular activity on spinal distribution of 125I-labelled tetanus toxin

    Naunyn-Schmiedeberg’s Arch. Pharmacol.

    (1973)
  • K.R. Aoki et al.

    Botulinum toxin type A: from toxin to therapeutic agent

    Eur. J. Neurol.

    (1997)
  • T. Anderson et al.

    Botulinum toxin treatment of spasmodic torticollis

    J. R. Soc. Med.

    (1992)
  • Cited by (0)

    View full text